| 09/05/24 | 07:00:06 | 9 May 2024 | | Annual Report & AGM Notice |
| 01/05/24 | 07:00:08 | 1 May 2024 | | Significant POLB 001 Patent Granted in USA |
| 30/04/24 | 07:02:00 | 30 Apr 2024 | | Appointment of Joint Broker |
| 30/04/24 | 07:01:00 | 30 Apr 2024 | | Option Agreement to Acquire Orphan Drug Candidate |
| 30/04/24 | 07:00:11 | 30 Apr 2024 | | Results for the year ended 31 December 2023 |
| 29/04/24 | 07:00:12 | 29 Apr 2024 | | TR-1: Notification of major holdings |
| 20/03/24 | 07:00:04 | 20 Mar 2024 | | POLB 001 US Patent Update |
| 22/02/24 | 07:00:09 | 22 Feb 2024 | | Director/PDMR Shareholding |
| 19/02/24 | 13:42:01 | 19 Feb 2024 | | Director Share Purchase |
| 15/02/24 | 07:00:06 | 15 Feb 2024 | | Board Role Change and Launch of EIP |
| 12/02/24 | 07:00:07 | 12 Feb 2024 | | Market Opportunity for POLB 001 for CRS |
| 17/01/24 | 07:00:05 | 17 Jan 2024 | | Further data shows POLB001 potential in cancer CRS |
| 20/12/23 | 07:00:12 | 20 Dec 2023 | | RSV AI Drug Candidate Analysis Update |
| 11/12/23 | 07:00:07 | 11 Dec 2023 | | POLB 001 Data Presented at ASH |
| 30/11/23 | 07:00:16 | 30 Nov 2023 | | Directorate Change |
| 21/11/23 | 07:00:13 | 21 Nov 2023 | | Immunomodulator II patent granted in Japan |
| 16/11/23 | 07:00:15 | 16 Nov 2023 | | POLB 001 LPS Trial Data to be Presented at IUIS |
| 09/11/23 | 07:00:15 | 9 Nov 2023 | | Former Amryt Pharma Leadership Team join Poolbeg |
| 03/11/23 | 07:05:48 | 3 Nov 2023 | | POLB001 Data to be Presented at ASH Annual Meeting |
| 01/11/23 | 07:00:10 | 1 Nov 2023 | | POLB 001 Oncology Programme Update Meeting |
| 26/10/23 | 07:00:14 | 26 Oct 2023 | | SAB Endorses Influenza Drug Targets |
| 17/10/23 | 07:00:09 | 17 Oct 2023 | | Poolbeg Partners with a Nasdaq-Listed Biopharma |
| 29/09/23 | 07:00:12 | 29 Sept 2023 | | Favourable Conclusion of Patent Opposition |
| 20/09/23 | 07:00:10 | 20 Sept 2023 | | Immunomodulator I Patent Portfolio Strengthened |
| 19/09/23 | 07:00:04 | 19 Sept 2023 | | Immunomodulator I Patent Opposition Withdrawal |
| 13/09/23 | 07:00:04 | 13 Sept 2023 | | Interim results for the six months to 30 June 2023 |
| 29/06/23 | 07:00:02 | 29 Jun 2023 | | AI led programme identifies influenza drug targets |
| 22/06/23 | 07:00:03 | 22 Jun 2023 | | Oral Vaccine Programme Moves Forward |
| 24/05/23 | 07:00:14 | 24 May 2023 | | Board Appointment |
| 11/05/23 | 14:27:09 | 11 May 2023 | | Results of Annual General Meeting |
| 12/04/23 | 07:00:06 | 12 Apr 2023 | | Annual Report & AGM Notice |
| 30/03/23 | 07:00:05 | 30 Mar 2023 | | Results for the year ended 31 December 2022 |
| 10/03/23 | 07:00:07 | 10 Mar 2023 | | Notification of Major Holdings |
| 09/03/23 | 15:51:42 | 9 Mar 2023 | | Notification of Major Holdings |
| 08/03/23 | 07:00:06 | 8 Mar 2023 | | POLB 001 patent portfolio strengthened |
| 02/03/23 | 11:05:38 | 2 Mar 2023 | | Second Price Monitoring Extn |
| 02/03/23 | 11:00:32 | 2 Mar 2023 | | Price Monitoring Extension |
| 02/03/23 | 07:00:08 | 2 Mar 2023 | | Positive Results POLB001 LPS Human Challenge Trial |
| 16/01/23 | 07:00:05 | 16 Jan 2023 | | Strategic expansion of POLB 001 into oncology |
| 09/01/23 | 09:05:50 | 9 Jan 2023 | | Second Price Monitoring Extn |
| 09/01/23 | 09:00:36 | 9 Jan 2023 | | Price Monitoring Extension |
| 09/01/23 | 07:00:02 | 9 Jan 2023 | | Positive Initial Data Analysis in POLB 001 Trial |
| 21/12/22 | 07:00:05 | 21 Dec 2022 | | Poolbeg identifies novel RSV drug candidates |
| 14/12/22 | 07:00:04 | 14 Dec 2022 | | Metabolic diseases oral delivery licence signed |
| 12/12/22 | 14:05:35 | 12 Dec 2022 | | Second Price Monitoring Extn |
| 12/12/22 | 14:00:30 | 12 Dec 2022 | | Price Monitoring Extension |
| 12/12/22 | 07:00:03 | 12 Dec 2022 | | POLB 001 LPS human challenge trial completed |
| 29/11/22 | 07:00:08 | 29 Nov 2022 | | Influenza AI model build completed |
| 18/11/22 | 14:00:48 | 18 Nov 2022 | | Price Monitoring Extension |
| 17/11/22 | 14:05:57 | 17 Nov 2022 | | Second Price Monitoring Extn |
